Decreased in Liver Fibrosis in Patients with HCV/HIV Coinfection After Treatment with Sofosbuvir/Daclatasvir

Authors

  • Andreas Jonathan Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Rudi Wisaksana Division of Infectious and Tropical Disease Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Nenny Agustanti Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung

DOI:

https://doi.org/10.24871/202201987-95

Keywords:

HCV/HIV coinfection, liver fibrosis, Sofosbuvir/Daclatasvir

Abstract

Background: Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) co-infection increases the progression of liver fibrosis to advanced liver disease and death. The aim of this study is to determine whether decreased of liver fibrosis occur in HCV/HIV coinfection patients after therapy with Sofosbuvir/daclatasvir.

 Method: This study used a quasi-experimental study design without a control group. The study subjects were HCV/HIV coinfection patients who received Sofosbuvir / daclatasvir therapy in the Gastroentero-Hepatology Clinic of Dr. Hasan Sadikin Hospital. In this study measurement of liver fibrosis was carried out by using AST to Platelet Ratio Index (APRI) and Fibrosis-4 Index (FIB-4) before therapy and when SVR-24 was achieved.

Results: The study involved 29 subjects. Most of the research subjects were men, with an average age of 40.38 years (SD 3.48). From the results of this study, we found a decrease in APRI scores and FIB-4 index when HCV / HIV coinfection patients, that were treated with Sofosbuvir/ Daclatasvir, achieved SVR 24. The median of APRI scores before therapy and after SVR-24 was decreased from 0.41 to 0.28 (95% CI: 0.01 - 0.23, p-value 0,01) and the median of FIB-4 Index before therapy and after the SVR 24 was decreased from 0.94 to 0.81 (95% CI: -0, 04 - 0.35, p-value 0.28).

Conclusion: This study concluded that therapy using Sofosbuvir / Daclatasvir in HCV / HIV coinfected patients has very good effectiveness and can reduce liver fibrosis.

Downloads

Published

2020-07-23

How to Cite

Jonathan, A., Wisaksana, R., & Agustanti, N. (2020). Decreased in Liver Fibrosis in Patients with HCV/HIV Coinfection After Treatment with Sofosbuvir/Daclatasvir. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 20(2), 87–95. https://doi.org/10.24871/202201987-95

Issue

Vol. 20 No. 2 (2019): VOLUME 20, NUMBER 2, August 2019

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).